Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Vanderbilt University |
---|---|
Information provided by: | Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00179231 |
The study involves a six-month, double-blind protocol during which eighty patients, across three sites around the country, will be randomly assigned to receive clozapine or olanzapine. The specific aims of the study are to evaluate the relative effects of olanzapine and clozapine on clinical outcomes and cognition in patients diagnosed with schizophrenia or schizoaffective disorder who have demonstrated resistance to treatment in the past.
Condition | Intervention |
---|---|
Schizophrenia Schizoaffective Disorder |
Drug: olanzapine vs. clozapine |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Uncontrolled, Parallel Assignment, Efficacy Study |
Estimated Enrollment: | 80 |
Study Start Date: | May 2000 |
Estimated Study Completion Date: | February 2004 |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 990172 |
Study First Received: | September 13, 2005 |
Last Updated: | September 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00179231 |
Health Authority: | United States: Food and Drug Administration |
Schizophrenia Mental Disorders Clozapine Olanzapine |
Psychotic Disorders Serotonin Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Gastrointestinal Agents Psychotropic Drugs Antiemetics Central Nervous System Depressants Antipsychotic Agents |
Serotonin Uptake Inhibitors Pharmacologic Actions GABA Antagonists Serotonin Antagonists Serotonin Agents Autonomic Agents Therapeutic Uses GABA Agents Peripheral Nervous System Agents Central Nervous System Agents |